Obesity, as defined by bodily weight (body weight) and by bodily conformation-derived variables, accompanies hypertension in many patients. Both conditions are independent cardiovascular risk factors. In a formal survey carried out in the adult general population of Uruguay (LATIR Study, 575 adult and elderly subjects of whom 41.6% were males), we found the prevalence of hypertension to be 28.5% (95% CI: 24.9-32.4%) and that 74.4% of hypertensive individuals had a body mass index (BMI) higher than 25 kg/m 2 (95% CI: 67.0-80.8%). This association between obesity and hypertension forms part of a broader relationship between body weight and blood pressure (BP). In the general population, BP bears a positive linear correlation with BMI and waist-to-hip ratio over the continuous ranges of normal and unfavourable values of these three variables (r = 0.42, P Ͻ 0.001 for the correlation between BMI and mean BP, LATIR Study). Patients who present hyperten-
Introduction
Obesity has detrimental effects on the health. [1] [2] [3] Due to present lifestyle conditions, the prevalence of obesity is growing rapidly. Severe obesity and weight gain among young individuals is associated with increased risk of mortality from coronary and heart disease and from all cardiovascular causes. [4] [5] [6] 
Body weight evaluation
Bodily fat may be evaluated by measuring body density with an hydrostatic instrument and referring this variable to bodily weight, or it may be assessed using tissue electrical impedance as the instrumental variable. 7 Body mass index (BMI), ie the ratio between body weight and the square of body height, is the commonly used continuous variable to assess bodily mass in epidemiological studies, since it corrects for height. 8, 9 Overweight is defined by a BMI equal to or higher than 25 kg/m 2 . Accumulation of fat in the abdomen is usually evaluated through the waist-to-hip ratio (WHR) . The WHR appears to be a stronger predictor of cardiovascular prognosis than bare overall obesity, [10] [11] [12] Correspondence: ME Díaz since it has been found to be associated with coronary heart disease and stroke (and also with overall mortality) even within the range of arbitrarily defined normal BMI values. 13, 14 Obesity, hypertension and cardiovascular risk
Body weight and hypertension
Obesity and weight gain have been identified as the most important determinants of hypertension. [15] [16] [17] [18] In the Framingham Study, it was found that a 10% rise in body weight explains a 7 mm Hg rise in systolic blood pressure (SBP) in the population at large. 19 It has also been found that every kilogram excess body weight that is lost is associated with decreases of 0.33 and 0.43 mm Hg in SBP and diastolic blood pressure (DBP) respectively. 20 The prevalence of hypertension in the NHANES II was 2.9 times higher in obese than in non-obese adults. Bodily weight and BP correlate positively over the normal and the arbitrarily defined abnormal ranges of these variables (Figure 1 ). 21 A high intake of sodium, which is a risk factor for the development of hypertension, was identified as a strong independent risk factor for coronary heart disease among obese individuals in the NHANES I. 22 The association between obesity and hypertension, which is independent of ethnicity and socio-S19 Figure 1 Relationship between mean blood pressure (BP), body mass index and age from a population survey carried out in Uruguay. 43 The quoted r value is the multiple linear correlation coefficient between mean BP and the two other variables.
economic condition, forms part of a broader relationship between body weight and BP.
Obesity as a general cardiovascular risk factor
Severe obesity and weight gain among young individuals are associated with increased risk of mortality from coronary and heart disease and from all cardiovascular causes. [4] [5] [6] Conditions that usually accompany obesity in hypertensive subjects Common findings in obese hypertensive patients include insulin resistance or type 2 diabetes, hypertriglyceridaemia, an unfavourable plasma cholesterol profile, and hyperuricaemia.
Left ventricular hypertrophy frequent occurs in non-hypertensive obese individuals, and it is even more frequent when hypertension accompanies diabetes.
Many obese hypertensive patients also present obstructive sleep apnea (OSA). The higher the body weight and the weight gain, the higher the prevalence of OSA in men. 23 The severity of OSA is positively associated with neck circumference (an indicator of body mass) and with other variables used to assess bodily fat, including WHR. More than 50% of the patients who present OSA have an overly high WHR. 24, 25 Hypertension and obesity and some of their associated conditions in the population of Uruguay
In a strictly randomised survey carried out in the adult general population in the city of Minas, UruJournal of Human Hypertension guay (LATIR Study, n = 575, 41.6% males), we found that the prevalence of hypertension is 28.5% (95% CI: 24.9-32.4%), and that 74.4% of hypertensive individuals have a BMI higher than 25 kg/m 2 (95% CI: 67.0-80.8%). 26 BP bears a positive linear relationship with BMI (r = 0.42, P Ͻ 0.001 for the correlation between BMI and mean BP) ( Figure 1 ) and with WHR over the continuous ranges of normal and unfavourable values of these three variables. BP, indicators of obesity and progressively unfavourably values of metabolic variables also correlate linearly ( Table 1) .
Pathogenesis of hypertension in obese subjects
Genetic factors, metabolic and endocrine abnormalities and environmental and psychosocial determinants, including calorie intake, unbalanced diets and decreased physical activity, appear to be involved in the pathogenesis of obesity. 12, 27, 28 Many obese and/or hypertensive subjects present genetically determined resistance to the adipocytesecreted hormone leptin and higher plasma levels of leptin than lean subjects; this hormone opposes fat accumulation, perhaps by increasing thermogenesis and appetite by an action on the central nervous system and as well a through a direct effect on brown adipose tissue. 29 An interesting hypothesis on the pathogenesis of hypertension in man postulates that this condition is largely determined by an enhanced expression of the natriuretic peptide clearance receptor (NPRC) in adipose tissue. It is based on the fact that hypertensive patients have been found to present low levels of atrial natriuretic peptide and decreased natriuresis and peptide regulation of aldosterone. These shifts, which could be due to enhanced activity of the NPRC, could well tend to elevate BP. 30 An hypothesis on the pathogenesis of hypertension in obese patients considers that the development of hypertension in genetically predisposed obese individuals may be triggered by an adaptive response to excess carbohydrate and fat intake which conveys a positive energy balance and an increase in plasma insulin. The latter change would elevate the activity of the central sympathetic nervous system, and thus increase cardiac activity and result in an increase in BP. 31, 32 The OSA syndrome has also been linked to the development of hypertension in obese individuals. The episodes of hypoxemia and hyperpcapnia, the sleep pattern disruption, the frequent arousals from sleep, and the accentuated intrathoracic pressure changes and their attending sympathetic activation that occur in individuals with OSA have all been incriminated as possibly contributing mechanisms for the development of hypertension. Two-sided values of P from contrasts between r and 0: *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001.
Pathophysiology of high blood pressure in obese subjects
Heart rate, pulse pressure and mean BP increase as functions of body weight. Obese hypertensive patients usually present elevated cardiac output, perhaps due to excess intravascular volume. Cardiac contractility is reduced in obese patients, who develop left ventricular hypertrophy early in the course of their disease. Diastolic ventricular dysfunction associated with left ventricular hypertrophy may contribute to the frequent occurrence of cardiovascular symptoms, including tachycardia and ventricular arrhythmias. Table 2 summarises the differences between obese and lean hypertensive patients and obese normotensive individuals with respect to cardiac and haemodynamic functions. These pathophysiological features, which have been thoroughfully investigated, are described and discussed in detail in an excellent review. 34 
Therapeutic intervention

Non-pharmacological treatment
The two most important objectives of therapeutic intervention in patients who present obesity and hypertension are to reduce body weight and BP. Bodily weight reductions usually convey decreases in high BP. Sodium restriction reduces BP and it must always be prescribed to obese hypertensive patients, in as much as many of these patients present intravascular volume expansion and left ventricular hypertrophy and both these conditions are negatively influenced by daily sodium intakes above 100 mmol.
Pharmacological treatment
Non-pharmacological treatment is usually insufficient and pharmacological treatment must be added to control BP in obese hypertensive patients.
Diuretics are a good choice since they counter volume expansion and reduce BP effectively when used at diuretic doses. 35 However, diuretics induce insulin resistance and glucose intolerance and may cause diabetes when used at these doses. Low, nonor minimally diuretic doses of these drugs used once daily lower BP and generally have negligible adverse metabolic effects. 36, 37 Twelve to 15 weeks should be allowed for the response of BP to low doses of diuretics to stabilise, and if necessary combination therapy should be instituted. 38 If factors such as lipid and/or carbohydrate metabolism are present, drugs such as angiotensin-converting enzyme (ACE) inhibitors might constitute the best choice for the first-line handling of hypertension in obese individuals. [39] [40] [41] This possibility merits being researched, since thus far no sufficiently powered trial has compared the effects of BP control with different classes of drugs on cardiovascular prognosis in obese hypertensive patients.
Regarding the influence of the sympathetic nervous system in obese hypertensive patients, its attenuation should be considered useful. Hypertension control with beta-blockers decreases cardiovascular risk in adult hypertensive patients at large; therefore, the members of this drug class that are not endowed with intrinsic sympathomimetic activity should be considered for hypertension in the obese. The balance between the possible adverse effects of beta-blockers on triglycerides and their possible beneficial action in obese hypertensive patients with left ventricular hypertrophy should be evaluated in purposely designed clinical trials.
Although alpha adrenergic blocking agents have a positive effect on serum lipids and do not alter and may even benefit carbohydrate and lipid metabolism, they may cause sodium and fluid retention. A recent report on an increase in cardiovascular mortality among subjects treated with these drugs
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suggests that alpha-1 adrenergic blockers should be limited to obese hypertensive patients who also present urological obstructive symptoms of benign prostate nature. 42 Total blockade of the sympathetic system by drugs acting on the central nervous system constitute a rational therapeutic option in obese hypertensive patients with associate metabolic conditions. Calcium antagonists are metabolically neutral, but dihydropyridine-type drugs increase heart rate and should not be considered a possible option. Nondihydropiridine calcium antagonists depress cardiac contractility, and their long-range effect on cardiovascular prognosis in obese hypertensive patients remains unknown.
ACE inhibitors seem to be effective, and they do not alter carbohydrate and lipid metabolism. Similar considerations hold with respect to angiotensin II receptor antagonists, although their presumed action in obese hypertensive patients still requires investigative sanction.
